Abstract

This Clinical Core is specifically designed and supported with the objective of facilitating the translational mission of the Pacific Northwest (PNW) Prostate Cancer SPORE. Each of the five major projects directly utilizes patient- derived materials and attendant clinical data, and most are designed with a patient-directed interventional trial. However, there are major barriers between clinical, basic and population-based research that constrain progress; thus, the Aims of this Core were formulated to assist the major projects, developmental projects, and career development awardees in the rapid advancement of their research objectives. The Clinical Core has the following Specific Aims:
Specific Aim 1 : To design, execute, accrue to, and otherwise facilitate the conduct and timely completion of human clinical trials relevant to SPORE translational science. The Clinical Core will support major research projects, developmental research studies, and clinical trials related to the Career Enhancement Program.
Specific Aim 2 : To design, direct, and assist with patient recruitment for biospecimen acquisition.
Specific Aim 3 : To direct, support, and enhance CAISIS (repository of clinical and patient-reported data) to support clinical and translational prostate cancer research across the SPORE sites.
Specific Aim 4 : To ensure that SPORE Major and Developmental Projects maintain a patient-centered focus, we will support and engage the SPORE Advocacy Committee in the activities of the SPORE.

Public Health Relevance

The Clinical Core will carry out the vital objective of supporting and engaging the patient community, who are so vital to the research efforts of the Projects; counsel, enroll, and treat patients on SPORE-related clinical trials; provide support to the rapid autopsy program and the clinical database, CAISIS; and be a resource to the clinical sites of the University of Washington, the University of British Columbia, Oregon Health and Science University, in all aspects of trial design and management.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-18
Application #
10016183
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-19
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109

  Publications

Barnard, Monique; Quanson, Jonathan L; Mostaghel, Elahe et al. (2018) 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183:192-201
Ganaie, Arsheed A; Beigh, Firdous H; Astone, Matteo et al. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models. Clin Cancer Res 24:6421-6432
Schweizer, Michael T; Haugk, Kathleen; McKiernan, Jožefa S et al. (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One 13:e0198389
Peacock, James W; Takeuchi, Ario; Hayashi, Norihiro et al. (2018) SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med 10:219-238
Pollan, Sara G; Huang, Fangjin; Sperger, Jamie M et al. (2018) Regulation of inside-out ?1-integrin activation by CDCP1. Oncogene 37:2817-2836
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14
Schweizer, Michael T; Hancock, Michael L; Getzenberg, Robert H et al. (2018) Hormone levels following surgical and medical castration: defining optimal androgen suppression. Asian J Androl 20:405-406
Yan, Qingxiang; Bantis, Leonidas E; Stanford, Janet L et al. (2018) Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. Stat Med 37:627-642
Lam, Hung-Ming; Nguyen, Holly M; Corey, Eva (2018) Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. Methods Mol Biol 1786:1-27
Lam, Hung-Ming; Corey, Eva (2018) Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol 8:167

Showing the most recent 10 out of 400 publications